

**Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE Trial of prolonged-release fampridine**

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J.

CNS drugs

2019; 33(1):61-79

**ARTICLE IDENTIFIERS**

DOI: 10.1007/s40263-018-0586-5

PMID: 30535670

PMCID: not available

**JOURNAL IDENTIFIERS**

LCCN: not available

pISSN: 1172-7047

eISSN: 1179-1934

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: not available

This article was identified from a query of the SafetyLit database.